Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
208 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Uveitis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H2 2017, provides an overview of the Uveitis (Ophthalmology) pipeline landscape. Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 5, 8, 5, 2, 25, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively. Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Uveitis - Overview 8 Uveitis - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 19 Uveitis - Therapeutics Assessment 20 Assessment by Target 20 Assessment by Mechanism of Action 23 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Uveitis - Companies Involved in Therapeutics Development 30 2-BBB Medicines BV 30 AbbVie Inc 30 Aciont Inc 31 Alcon Laboratories Inc 31 Aldeyra Therapeutics Inc 31 Apitope International NV 32 Bionomics Ltd 32 Bristol-Myers Squibb Co 33 Can-Fite BioPharma Ltd 33 Clearside BioMedical Inc 34 Coherus BioSciences Inc 34 Elasmogen Ltd 35 Endocyte Inc 35 Enzo Biochem Inc 35 EyeGate Pharmaceuticals Inc 36 Eyevensys SAS 36 F. Hoffmann-La Roche Ltd 37 Galapagos NV 37 HanAll Biopharma Co Ltd 38 Icon Bioscience Inc 38 Idera Pharmaceuticals Inc 38 Johnson & Johnson 39 KPI Therapeutics Inc 39 Midatech Pharma Plc 40 Mitotech SA 40 Nemus Bioscience Inc 41 Novartis AG 41 Oculis ehf 42 OncoNOx ApS 42 Ophthotech Corp 42 Orchid Pharma Ltd 43 Palatin Technologies Inc 43 Panoptes Pharma GesmbH 44 pSivida Corp 44 Re-Pharm Ltd 45 Santen Pharmaceutical Co Ltd 45 SynDevRx Inc 45 TxCell SA 46 Uveitis - Drug Profiles 47 2B-3201 - Drug Profile 47 abatacept - Drug Profile 49 adalimumab - Drug Profile 58 adalimumab biosimilar - Drug Profile 67 adalimumab biosimilar - Drug Profile 70 adalimumab biosimilar - Drug Profile 73 adalimumab biosimilar - Drug Profile 74 ADX-102 - Drug Profile 75 Antisense Oligonucleotide to Inhibit NLRP3 for Inflammatory Disorders - Drug Profile 81 Antisense RNAi Oligonucleotide to Inhibit ProRenin Receptor for Uveitis and Diabetic Retinopathy - Drug Profile 82 ANV-103 - Drug Profile 83 ATXUV-1 - Drug Profile 84 avacincaptad pegol sodium - Drug Profile 85 B27-PD - Drug Profile 88 BNC-164 - Drug Profile 89 Col-Treg - Drug Profile 90 CVX-001 - Drug Profile 92 cyclosporine SR - Drug Profile 93 dalazatide - Drug Profile 94 dexamethasone acetate - Drug Profile 99 dexamethasone acetate - Drug Profile 105 dexamethasone sodium phosphate - Drug Profile 107 Drug for Chronic Uveitis - Drug Profile 109 Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 110 EBI-031 - Drug Profile 111 EC-1669 - Drug Profile 112 ELN-21 - Drug Profile 113 ELN-22 - Drug Profile 114 EYS-606 - Drug Profile 115 filgotinib - Drug Profile 116 fluocinolone acetonide SA - Drug Profile 129 fluocinolone acetonide SR - Drug Profile 130 FR-104 - Drug Profile 139 Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis - Drug Profile 142 HL-036 - Drug Profile 143 HO-10 - Drug Profile 144 IVMED-10 - Drug Profile 145 IVMED-20 - Drug Profile 146 KPI-190 - Drug Profile 147 latanoprost SR - Drug Profile 148 LME-636 - Drug Profile 149 lodamin - Drug Profile 150 methotrexate - Drug Profile 151 NB-2222 - Drug Profile 152 OX-1001 - Drug Profile 153 piclidenoson - Drug Profile 154 PL-8177 - Drug Profile 164 plastoquinone decyl triphenylphosphonium bromide - Drug Profile 165 PP-001 - Drug Profile 167 PPL-003 - Drug Profile 169 RP-0217 - Drug Profile 171 sirolimus - Drug Profile 172 Small Molecule to Inhibit PDE4B and TNF Alpha for Asthma, COPD and Uveitis - Drug Profile 176 Small Molecules to Inhibit 5-Lipoxygenase for Uveitis - Drug Profile 177 Small Molecules to Inhibit TYK2 for Psoriasis and Uveitis - Drug Profile 178 tesidolumab - Drug Profile 179 triamcinolone acetonide - Drug Profile 181 Uveitis - Dormant Projects 188 Uveitis - Discontinued Products 191 Uveitis - Product Development Milestones 192 Featured News & Press Releases 192 Appendix 203 Methodology 203 Coverage 203 Secondary Research 203 Primary Research 203 Expert Panel Validation 203 Contact Us 203 Disclaimer 204
List of Tables
Number of Products under Development for Uveitis, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Uveitis - Pipeline by 2-BBB Medicines BV, H2 2017 Uveitis - Pipeline by AbbVie Inc, H2 2017 Uveitis - Pipeline by Aciont Inc, H2 2017 Uveitis - Pipeline by Alcon Laboratories Inc, H2 2017 Uveitis - Pipeline by Aldeyra Therapeutics Inc, H2 2017 Uveitis - Pipeline by Apitope International NV, H2 2017 Uveitis - Pipeline by Bionomics Ltd, H2 2017 Uveitis - Pipeline by Bristol-Myers Squibb Co, H2 2017 Uveitis - Pipeline by Can-Fite BioPharma Ltd, H2 2017 Uveitis - Pipeline by Clearside BioMedical Inc, H2 2017 Uveitis - Pipeline by Coherus BioSciences Inc, H2 2017 Uveitis - Pipeline by Elasmogen Ltd, H2 2017 Uveitis - Pipeline by Endocyte Inc, H2 2017 Uveitis - Pipeline by Enzo Biochem Inc, H2 2017 Uveitis - Pipeline by EyeGate Pharmaceuticals Inc, H2 2017 Uveitis - Pipeline by Eyevensys SAS, H2 2017 Uveitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Uveitis - Pipeline by Galapagos NV, H2 2017 Uveitis - Pipeline by HanAll Biopharma Co Ltd, H2 2017 Uveitis - Pipeline by Icon Bioscience Inc, H2 2017 Uveitis - Pipeline by Idera Pharmaceuticals Inc, H2 2017 Uveitis - Pipeline by Johnson & Johnson, H2 2017 Uveitis - Pipeline by KPI Therapeutics Inc, H2 2017 Uveitis - Pipeline by Midatech Pharma Plc, H2 2017 Uveitis - Pipeline by Mitotech SA, H2 2017 Uveitis - Pipeline by Nemus Bioscience Inc, H2 2017 Uveitis - Pipeline by Novartis AG, H2 2017 Uveitis - Pipeline by Oculis ehf, H2 2017 Uveitis - Pipeline by OncoNOx ApS, H2 2017 Uveitis - Pipeline by Ophthotech Corp, H2 2017 Uveitis - Pipeline by Orchid Pharma Ltd, H2 2017 Uveitis - Pipeline by Palatin Technologies Inc, H2 2017 Uveitis - Pipeline by Panoptes Pharma GesmbH, H2 2017 Uveitis - Pipeline by pSivida Corp, H2 2017 Uveitis - Pipeline by Re-Pharm Ltd, H2 2017 Uveitis - Pipeline by Santen Pharmaceutical Co Ltd, H2 2017 Uveitis - Pipeline by SynDevRx Inc, H2 2017 Uveitis - Pipeline by TxCell SA, H2 2017 Uveitis - Dormant Projects, H2 2017 Uveitis - Dormant Projects, H2 2017 (Contd..1), H2 2017 Uveitis - Dormant Projects, H2 2017 (Contd..2), H2 2017 Uveitis - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
